Source: Reunion Neuroscience (formerly Field Trip Health)
  • Reunion Neuroscience (REUN) has filed a lawsuit against Mindset Pharma in the United States District Court
  • The company alleges that Mindset knowingly copied Reunion’s RE104 compound and misleadingly presented it to the Patent Office as Mindset’s invention
  • Reunion has also asserted claims for co-ownership of the ‘353 Patent and breach of contract
  • Reunion Neuroscience early-stage pharmaceutical company developing therapeutic solutions for mental health conditions
  • Reunion Neuroscience Inc. (TSX:REUN) opened trading at C$1.18

Reunion Neuroscience (REUN) has filed a lawsuit against Mindset Pharma in the United States District Court for the District of New Jersey.

The company alleges that Mindset knowingly copied Reunion’s RE104 compound and misleadingly presented that exact composition to the Patent Office as Mindset’s invention while applying for U.S. Patent No. 11,591,353 (‘353 Patent). Reunion seeks to add the original and sole inventor of Reunion’s RE104, Reunion’s Chief Scientific Officer, Dr. Nathan Bryson, as an inventor of the ‘353 Patent.

Reunion has also asserted claims for co-ownership of the ‘353 Patent, inequitable conduct in the prosecution of the ‘353 Patent, and breach of contract.

About Reunion Neuroscience Inc.

Reunion Neuroscience early-stage pharmaceutical company developing therapeutic solutions for mental health conditions. The company’s lead asset, RE104, a proprietary, novel, serotonergic psychedelic compound, is being developed as a potential treatment for postpartum depression that could provide rapid symptom relief. Reunion is also developing the RE200 series, which includes preclinical compounds to address additional therapeutic applications.

Reunion Neuroscience Inc. (TSX:REUN) opened trading at C$1.18.


More From The Market Online

Myriad Uranium secures mining lease at Copper Mountain

Myriad Uranium (CSE:M) has entered into a 20-year mining lease with Diamond X Ranch for the Copper Mountain Uranium Project.

@ the Bell: Global markets make a comeback, but gold sinks

Canada’s main stock index followed markets around the globe on Monday and marched higher, recouping some losses from the dud of a week prior.

Eric Sprott tops up investment in gold stock Rio2

Eric Sprott adds C$2,000,115 to his position in Rio2 (TSXV:RIO), a junior mining stock developing its Fenix gold project in Chile.